NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options, according to data from two phase 3 trials.
During a symposium at the American Diabetes Association Scientific Sessions, researchers presented data from phase 3 trials investigating retatrutide (Eli Lilly), a once-weekly injectable GLP-1/GIP/glucagon triple hormone agonist. In the TRIUMPH-1 trial, the medication led to weight loss of up to 25% at 80 weeks and up to 29.9% at 104 weeks with the highest dose, as well as

NEW ORLEANS — Continuous glucose monitoring may have a role for adults with type 2 diabetes who are not using insulin, according to results from the CONNECT trial.
“We know that CGM has been shown to be effective for individuals with any type of diabetes using insulin, but the data for the effectiveness of CGM for individuals with type 2 diabetes not on insulin is not as robust,” Thomas W. Martens, MD, medical director at the International Diabetes Center, an affiliate of HealthPartners Institute in Minneapolis, and consultant in internal medicine at Park Nicollet Clinic, said during a

NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented at the American Diabetes Association Scientific Sessions.
Acmopatide (Roche), formerly known as CT-868, delivered a wide range of benefits among people with type 1 diabetes. Beyond improvements in HbA1c and body weight, participants receiving 4.1 mg or 6.6 mg of the study drug also had improvements in blood pressure and heart rate than those receiving placebo.
Despite these benefits, Jeremy Pettus, MD, associate

NEW ORLEANS — A next-generation automated insulin delivery algorithm was tied to improved glycemic outcomes compared with a currently available system, according to data presented at the American Diabetes Association Scientific Sessions.
In the STRIVE trial, researchers assessed glycemic outcomes, insulin delivery and device usage among people with type 1 or type 2 diabetes using the next-generation Omnipod 6 (Insulet) automated insulin delivery algorithm compared with Omnipod 5 (Insulet). The Omnipod 6 system was tied to improved time in range for adults compared with Omnipod 5, and

WASHINGTON — At the American Society of Cataract and Refractive Surgery meeting, VirtuaLens highlighted self-guided mode for its Immersive IOL Simulator.
The headset is designed to allow patients to compare monofocal, multifocal and premium IOL options through real-life scenario simulation, and self-guided mode minimizes the need for staff involvement through “streamlined, scalable patient workflows,” according to a press release from VirtuaLens.
{{VIDEO}}
During the meeting, Robert H. Osher, MD, of Cincinnati Eye Institute, told Healio that the technology gives patients the ability to test

PARK CITY, Utah — Previously published research has shown that CrossFit results in similar injury rates compared with other recreational sports, according to a presenter here.
“CrossFit has similar injury risk to other recreational sports that people are doing and does provide a broad framework to cover multiple domains of fitness that are unique,” Laura Vogel, MD, of Banner Medical Group, told Healio. “I would not want people to be discouraged from participating because of the conceptions about the sport that have been in the media and other areas.”
In her presentation at the International